Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL.

Biol Blood Marrow Transplant. 2018 Nov 10. pii: S1083-8791(18)30698-0. doi: 10.1016/j.bbmt.2018.11.004. [Epub ahead of print]

PMID:
30423480
2.

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors.

Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE.

Haematologica. 2018 Oct 31. pii: haematol.2018.200121. doi: 10.3324/haematol.2018.200121. [Epub ahead of print]

3.

Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors.

Chopade P, Akard LP.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):710-723. doi: 10.1016/j.clml.2018.06.029. Epub 2018 Jul 4. Review.

5.

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.

Ailawadhi S, Akard LP, Miller CB, Jillella A, DeAngelo DJ, Ericson SG, Lin F, Warsi G, Radich J.

Ther Adv Hematol. 2017 Jan;8(1):3-12. doi: 10.1177/2040620716678118. Epub 2016 Nov 24.

6.

Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.

Caldemeyer L, Akard LP.

Leuk Lymphoma. 2016 Dec;57(12):2739-2751. Epub 2016 Aug 10. Review.

PMID:
27562641
7.

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.

Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Keir C, Warsi G, Lin FP, Mauro MJ.

Clin Lymphoma Myeloma Leuk. 2016 May;16(5):286-96. doi: 10.1016/j.clml.2016.02.002. Epub 2016 Feb 16.

8.

Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.

Akard LP, Bixby D.

Leuk Lymphoma. 2016 May;57(5):1002-14. doi: 10.3109/10428194.2015.1122779. Epub 2016 Jan 4. Review.

PMID:
26726949
9.

Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.

Goldberg SL, Akard LP, Dugan MJ, Faderl S, Pecora AL.

J Oncol Pract. 2015 May;11(3):e398-404. doi: 10.1200/JOP.2014.001099. Epub 2015 Mar 10.

PMID:
25758446
10.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H; COMFORT-I investigators.

Haematologica. 2015 Apr;100(4):479-88. doi: 10.3324/haematol.2014.115840. Epub 2015 Jan 23.

11.

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.

Akard LP, Cortes JE, Albitar M, Goldberg SL, Warsi G, Wetzler M, Ericson SG, Radich JP.

Arch Pathol Lab Med. 2014 Sep;138(9):1186-92. doi: 10.5858/arpa.2013-0584-OA. Epub 2013 Dec 5.

PMID:
24308645
12.

Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.

Jabbour EJ, Bixby D, Akard LP.

Clin Adv Hematol Oncol. 2012 Dec;10(12 Suppl 22):1-16.

PMID:
23271195
13.

Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners.

Akard LP, Wang YL.

Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):385-95. doi: 10.1016/j.clml.2011.01.001. Epub 2011 May 10. Review.

PMID:
21723805
14.

Second-generation BCR-ABL kinase inhibitors in CML.

Akard LP.

N Engl J Med. 2010 Oct 21;363(17):1672-3; author reply 1673-5. doi: 10.1056/NEJMc1007927. No abstract available.

PMID:
20973144
15.

Transportation of peripheral blood progenitor cell products: effect of ambient temperature.

Jansen J, Nolan PL, Reeves MI, Morgan JA, Akard LP, Thompson JM, Dugan MJ, Hanks SG.

Cytotherapy. 2010 Nov;12(7):919-23. doi: 10.3109/14653240903580288.

PMID:
20429789
16.

Transportation of peripheral blood progenitor cell products: effects of time, temperature and cell concentration.

Jansen J, Nolan PL, Reeves MI, Akard LP, Thompson JM, Dugan MJ, Hanks SG.

Cytotherapy. 2009;11(1):79-85. doi: 10.1080/14653240802666050.

PMID:
19153854
17.

Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilization.

Thompson JM, Carlton P, Akard LP, Dugan MJ, Jansen J.

Transfusion. 2009 Mar;49(3):548-54. doi: 10.1111/j.1537-2995.2008.02006.x. Epub 2008 Nov 25.

PMID:
19040494
18.

Slow platelet recovery after PBPC transplantation from unrelated donors.

Jansen J, Hanks SG, Akard LP, Morgan JA, Nolan PL, Dugan MJ, Reeves MI, Thompson JM.

Bone Marrow Transplant. 2009 Mar;43(6):499-505. doi: 10.1038/bmt.2008.346. Epub 2008 Nov 10.

PMID:
18997834
19.

Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.

Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai LC, Akard LP, Hoffman R, Rondelli D.

Br J Haematol. 2008 Apr;141(1):80-3. doi: 10.1111/j.1365-2141.2008.07010.x.

PMID:
18324970
20.

Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?

Jansen EM, Hanks SG, Terry C, Akard LP, Thompson JM, Dugan MJ, Jansen J.

Transfusion. 2007 May;47(5):817-23.

PMID:
17465946
21.

Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.

Jansen J, Akard LP, Wack MF, Thompson JM, Dugan MJ, Leslie JK, Mattison R.

Mycoses. 2006 Sep;49(5):397-404.

PMID:
16922792
22.

Transplantation of hematopoietic stem cells from the peripheral blood.

Jansen J, Hanks S, Thompson JM, Dugan MJ, Akard LP.

J Cell Mol Med. 2005 Jan-Mar;9(1):37-50. Review.

23.
24.

Impaired PBPC collection in patients with myeloma after high-dose melphalan.

Jansen J, Thompson J, Dugan M, Wiemann M, Hanks S, Greenspan A, Akard L.

Cytotherapy. 2004;6(5):498-504.

PMID:
15512916
25.

Peripheral blood progenitor cell transplantation.

Jansen J, Thompson JM, Dugan MJ, Nolan P, Wiemann MC, Birhiray R, Henslee-Downey PJ, Akard LP.

Ther Apher. 2002 Feb;6(1):5-14. Review.

PMID:
11886571
26.

Longitudinal study of adaptation to the stress of bone marrow transplantation.

Fife BL, Huster GA, Cornetta KG, Kennedy VN, Akard LP, Broun ER.

J Clin Oncol. 2000 Apr;18(7):1539-49.

PMID:
10735903
27.

Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34+ cell collections are not necessarily cost-effective.

Akard LP, Thompson JM, Dugan MJ, Wiemann M, Greenspan A, Hanks S, Swinney M, Nyhuis A, Jansen J.

Biol Blood Marrow Transplant. 1999;5(6):379-85.

28.

Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF.

Jansen J, Thompson EM, Hanks S, Greenspan AR, Thompson JM, Dugan MJ, Akard LP.

Bone Marrow Transplant. 1999 Jun;23(12):1251-6.

29.

Characterization and partial purification of CD34+ progenitor cell ecto-phosphatidic acid phosphohydrolase.

Harvey KA, Siddiqui RA, Reeves M, Kovala T, Dugan M, Akard LP, English D.

Biochem Mol Biol Int. 1999 Jan;47(1):9-23.

PMID:
10092941
30.

Chemotactic migration triggers IL-8 generation in neutrophilic leukocytes.

Siddiqui RA, Akard LP, Garcia JG, Cui Y, English D.

J Immunol. 1999 Jan 15;162(2):1077-83.

31.

Characterization and purification of neutrophil ecto-phosphatidic acid phosphohydrolase.

English D, Martin M, Harvey KA, Akard LP, Allen R, Widlanski TS, Garcia JG, Siddiqui RA.

Biochem J. 1997 Jun 15;324 ( Pt 3):941-50.

32.

Impaired stem cell collection by consecutive courses of high-dose mobilizing chemotherapy using cyclophosphamide, etoposide, and G-CSF.

Akard LP, Wiemann M, Thompson JM, Swinney M, Lynn K, Hanks S, Jansen J.

J Hematother. 1996 Jun;5(3):271-7.

PMID:
8817394
33.

Growth factor induction of cytosolic protein tyrosine kinase activity in human haemopoietic progenitor cells isolated by flow cytometry.

Harvey KA, Siddiqui RA, Jansen J, Akard LP, Thompson JM, Cui Y, Chang Q, English D.

Br J Haematol. 1996 Jun;93(3):515-26.

PMID:
8652368
34.

Immunomagnetic CD4+ and CD8+ cell depletion for patients at high risk for severe acute GVHD.

Jansen J, Hanks S, Akard LP, Thompson JM, Burns S, Chang Q, English D, Garrett P.

Bone Marrow Transplant. 1996 Mar;17(3):377-82.

PMID:
8704690
35.

Cytosolic inactivation of translocated neutrophil plasma membrane protein tyrosine phosphatase.

Cui Y, Harvey KA, Siddiqui RA, Jansen J, Akard LP, Thompson JM, Garcia JG, English D.

Blood. 1996 Jan 1;87(1):341-9.

36.

Successful allogeneic bone marrow transplantation in an adult with aplastic anemia following orthotopic liver transplantation for non-A, non-B, non-C hepatitis.

Dugan MJ, Rouch DA, Akard LP, Sperl BG, Black JR, Markham RE Jr, Jansen J.

Bone Marrow Transplant. 1993 Oct;12(4):417-419.

PMID:
8275044
37.

Gp-regulated phosphoinositide hydrolysis in turkey and human erythrocytes exposed to fluoride ion: relationship to calcium influx.

English D, Akard LP, Taylor GS, Rizzo MT, Dominguez J, Garcia JG.

J Lab Clin Med. 1992 Jan;119(1):87-98.

PMID:
1309378
38.

Semiautomated processing of bone marrow grafts for transplantation.

English D, Lamberson R, Graves V, Akard LP, McCarthy LJ, Jansen J.

Transfusion. 1989 Jan;29(1):12-6.

PMID:
2643209
39.
42.

Cell-free activation of phagocyte NADPH-oxidase: tissue and differentiation-specific expression of cytosolic cofactor activity.

Parkinson JF, Akard LP, Schell MJ, Gabig TG.

Biochem Biophys Res Commun. 1987 Jun 30;145(3):1198-204.

PMID:
3038092
44.

Alpha-interferon and immune hemolytic anemia.

Akard LP, Hoffman R, Elias L, Saiers JH.

Ann Intern Med. 1986 Aug;105(2):306. No abstract available.

PMID:
3729223

Supplemental Content

Loading ...
Support Center